Relapsed/Refractory AML
4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
ApollomicsFOSTER CITY, CA
2 programs1
1
UproleselanPhase 31 trial
UproleselanPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ApollomicsUproleselan
ApollomicsUproleselan
Nkarta TherapeuticsNKX101 - CAR NK cell therapy
AmgenAMG 330
Clinical Trials (4)
Total enrollment: 95 patients across 4 trials
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Start: Nov 2021Est. completion: Aug 2024
Phase 3Terminated
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
Start: Feb 2021Est. completion: Jun 2024
Phase 1Completed
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Start: Sep 2020Est. completion: Jul 2039
Phase 1Active Not Recruiting
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Start: Aug 2015Est. completion: Jan 202295 patients
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space